- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05739474
Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children
Randomized, Double-blind, Comparative, Controlled Trial of Tolerability, Safety and Immunogenicity of the Flu-M Tetra Vaccine in Children Between 6 Months and 17 Years Old
Study Overview
Status
Intervention / Treatment
Detailed Description
The trial will be conducted in three stages.
• Stage I Participants - children aged 10 to 17 years (10 years 0 months 0 days - 17 years 11 months 30 days), will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine or the VaxigripTetra vaccine intramuscularly.
Once reviewed by the Sponsor, the report will be submitted to the supervisory executive authorities alongside the notice of commencement of Stage II trial.
• Stage II Participants - children aged 3 to 9 years (3 years 0 months 0 days - 9 years 11 months 30 days), will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine or the VaxigripTetra vaccine intramuscularly (double dose for volunteers who have not been vaccinated before).
Once reviewed by the Sponsor, the report will be submitted to the supervisory executive authorities alongside the notice of commencement of Stage III trial.
• Stage III Participants - children aged 6 to 35 months (6 months 0 days - 35 months 30 days), will be vaccinated twice 0.25 mL dose of the Flu-M Tetra vaccine or the VaxigripTetra vaccine intramuscularly.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Ellina Ruzanova, PhD
- Phone Number: (812) 660-06-39
- Email: e.a.ruzanova@niivs.ru
Study Contact Backup
- Name: Alla Emelyanova, PhD
- Phone Number: (812) 660-06-39
- Email: a.b.emelyanova@niivs.ru
Study Locations
-
-
-
Ekaterinburg, Russian Federation
- Active, not recruiting
- State Autonomous Health Care Institution of the Sverdlovsk Region "Children's City Clinical Hospital No. 11"
-
Engel's, Russian Federation
- Recruiting
- State Autonomous Health Care Institution "Engels City Clinical Hospital No1"
-
Contact:
- Oksana Nesterenko, PhD
-
Moscow, Russian Federation
- Recruiting
- LLC "Olla-Med"
-
Contact:
- Maria Plekhanova, MD
-
Perm, Russian Federation
- Not yet recruiting
- LLC "Professorskaya Clinica"
-
Contact:
- Svetlana Teplykh, PhD
-
Perm, Russian Federation
- Active, not recruiting
- State Budgetary Healthcare Institution of the Perm Territory "City Children's Clinical Clinic No. 5"
-
Saint Petersburg, Russian Federation
- Recruiting
- LLC PiterClinica
-
Contact:
- Tatiana Pak, PhD
-
Saratov, Russian Federation
- Recruiting
- LLC "DNA Research Center"
-
Contact:
- Inna Gamova, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For volunteers aged 10 to 17 years:
- Healthy children of both sexes aged 10 to 17 years (10 years 0 months 0 days - 17 years 11 months 30 days);
- The availability of written and dated informed consent of the volunteer (children aged 14 to 17 years) and their parent / legally acceptable representative for participation in the trial;
- If the volunteer has sexual relations, effective contraception methods must be used during the 30 days preceding vaccination and consent must be obtained to continue using these contraceptive methods during the trial and for two months after vaccination;
- The girls with menses in the medical history shall have a negative pregnancy test result.
For volunteers aged 3 to 9 years:
- Healthy children of both sexes aged 3 to 9 years (3 years 0 months 0 days - 9 years 11 months 30 days);
- The availability of written and dated informed consent of a parent / legally acceptable representative for participation in the trial;
For volunteers aged 6 to 35 months:
- Healthy children of both genders aged 6 to 35 months, inclusive (6 months 0 days - 35 months 30 days);
- The availability of written and dated informed consent of a parent / legally acceptable representative for participation in the trial.
- The trial subject of the was born full-term, with the Apgar score of 7-10 points.
For all volunteers:
The ability of a volunteer's parents / legally acceptable representatives to perform the requirements of the Protocol (i.e., fill out the Patient Diary, attend visits together with the volunteer).
Exclusion Criteria:
- History of influenza (including in mothers for children aged 6 to 35 months) or previous influenza vaccination during 6 months before the trial;
- Vaccination of the pregnant woman in the 2nd-3rd trimester (for the age group of 6 - 35 months) with an influenza vaccine
- Positive result of the SARS-CoV-2 test;
- Vaccination with any vaccine less than 30 days before participating in the trial or scheduled vaccination with any vaccine within 30 days after vaccination with the trial vaccines;
- A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter at the injection site) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination), encephalopathy;
- Allergic reactions to vaccine components or any previous vaccination;
- History of allergic reaction to chicken protein;
- History of cancer, leukemia, tuberculosis, autoimmune diseases;
- Carriage of HIV, syphilis, hepatitis B and C in the medical history, including by parents / legally acceptable representatives;
- Children who received immunoglobulin products or transfusions of whole blood or its components less than 3 months before the start of the trial;
- Long-term use (more than 14 days) of any immunomodulating medicines less than 3 months before the start of the trial;
- Any confirmed or suspected immunosuppressive or immunodeficiency condition;
- History of chronic diseases of the cardiovascular, bronchopulmonary, endocrine systems, blood in the acute stage (recovery less than 4 weeks before vaccination) or in the decompensation stage;
- Children with hemophilia who may develop bleeding after intramuscular injection;
- History of progressive neurological pathology, convulsive syndrome, afebrile convulsions;
- History of acute infectious diseases (fever ≥ 37.5°С): recovery less than 2 weeks before vaccination;
- Participation in another clinical trial less than 3 months before the start of the trial;
- History of mental illness of the child and the volunteer's parents;
- The history of the volunteer's parent / legally acceptable representative being registered with a tuberculosis dispensary and/or a narcological dispensary;
- Maternal history of drug use or alcohol abuse during pregnancy and/or breastfeeding;
- Pronounced congenital malformations in a child;
- Suspected developmental delay in a child.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Flu-M Tetra vaccine, children aged 10 to 17 years old
Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly
|
solution for intramuscular injection, 1 dose (0.5 mL)
Other Names:
suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
Other Names:
|
Active Comparator: VaxigripTetra vaccine, children aged 10 to 17 years old
Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly
|
solution for intramuscular injection, 1 dose (0.5 mL)
Other Names:
suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
Other Names:
|
Experimental: Flu-M Tetra vaccine, children aged 3 to 9 years old
Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
|
solution for intramuscular injection, 1 dose (0.5 mL)
Other Names:
suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
Other Names:
|
Active Comparator: VaxigripTetra vaccine, children aged 3 to 9 years old
Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
|
solution for intramuscular injection, 1 dose (0.5 mL)
Other Names:
suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
Other Names:
|
Experimental: Flu-M Tetra vaccine, children aged 6 to 35 months old
Сhildren will be vaccinated twice 0.25 mL dose of the Flu-M Tetra vaccine intramuscularly
|
solution for intramuscular injection, 1 dose (0.5 mL)
Other Names:
suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
Other Names:
|
Active Comparator: VaxigripTetra vaccine, children aged 6 to 35 months old
Сhildren will be vaccinated twice 0.25 mL dose of the VaxigripTetra vaccine intramuscularly
|
solution for intramuscular injection, 1 dose (0.5 mL)
Other Names:
suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline Geometric mean titer (GMT) ratio of antibodies for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Geometric mean titer (GMT) of antibodies in the blood serums of vaccinated participants in haemagglutination inhibition assay
|
Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline Seroconversion factor for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Seroconversion factor is an increase in the geometric mean titers of antibodies at Day 28 vs. the baseline level, expressed in the fold rise
|
Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Change from Baseline Seroprotection rate for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Seroprotection rate refers to the percentage of subjects with a generated protective HA titer (at least 1:40) vs. the baseline level
|
Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Change from Baseline Seroconversion rate for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Seroconversion rate refers to the percentage of subjects who have a prevaccination titer of influenza haemagglutinin antibody titer (HA titer) ≤ 1:10 and a post-vaccination HA titer ≥ 1:40 or a prevaccination HA titer > 1:10 and at least a 4-fold increase in post-vaccination HA titer vs. the baseline
|
Baseline (day 1) and 28 days after vaccination (Stage I, II, III) and revaccination (Stage II, III)
|
Incidence of immediate adverse events (allergic reactions)
Time Frame: 2 hours after vaccination
|
2 hours after vaccination
|
|
Incidence of local adverse events
Time Frame: 7 days after vaccination
|
7 days after vaccination
|
|
Incidence of systemic adverse events
Time Frame: 7 days after vaccination
|
7 days after vaccination
|
|
Incidence of other adverse reactions
Time Frame: Days 8 to 28 after vaccination
|
Days 8 to 28 after vaccination
|
|
Incidence of severe adverse events
Time Frame: Days 1 to 28+3 (for participants with 1 vaccination), Day 1 to 56±3 (for participants with vaccination and revaccination)
|
Days 1 to 28+3 (for participants with 1 vaccination), Day 1 to 56±3 (for participants with vaccination and revaccination)
|
|
Withdrawal of a volunteer from the trial due to development of an AE/SAE associated with the use of the trial products
Time Frame: Days 1 to 28+3 (for participants with 1 vaccination), Day 1 to 56±3 (for participants with vaccination and revaccination)
|
Days 1 to 28+3 (for participants with 1 vaccination), Day 1 to 56±3 (for participants with vaccination and revaccination)
|
|
Number of participants with abnormal physical examination findings
Time Frame: Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Physical examination of volunteers includes an interview, discovery of complaints and symptoms, when required, palpation, auscultation, percussion. It is necessary to conduct an examination of the following organs and systems: skin, mucosa, eyes, oral cavity and pharynx, lungs/chest, heart/cardiovascular system, abdominal organs, nervous system, lymph nodes, musculoskeletal system |
Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Number of participants with abnormal changes in vital signs - Blood pressure (BP)
Time Frame: Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
BP is assessed in children aged 36 months and older.
BP measurements include the systolic and diastolic blood pressure.
|
Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Number of participants with abnormal changes in vital signs - Heart rate (HR)
Time Frame: Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
HR is measured using a phonendoscope at the apex of the heart during 1 minute.
|
Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Number of participants with abnormal changes in vital signs - Respiratory rate (RR)
Time Frame: Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
RR is counted with a hand placed on the child's chest or abdomen or by holding a stethoscope at the child's nose.
The measurement is conducted during one minute.
|
Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Number of participants with abnormal changes in vital signs - Body temperature
Time Frame: Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
The body temperature is measured with a digital thermometer.
|
Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Number of participants with clinically significant abnormalities - Complete blood count (CBC)
Time Frame: Days 1, 3
|
Hemoglobin, Hematocrit, Erythrocytes, Leukocytes, Leukocytic Formula, Platelets, Erythrocyte Sedimentation Rate (ESR)
|
Days 1, 3
|
Number of participants with clinically significant abnormalities - Biochemical blood test (BBT)
Time Frame: Days 1, 3
|
ALT, AST, Alkaline Phosphatase, Total Bilirubin, Total Protein, Urea, Glucose
|
Days 1, 3
|
Number of participants with clinically significant abnormalities - Urinalysis
Time Frame: Days 1, 3
|
pH, Color, Relative Density/Specific Gravity, Protein, Glucose, Red Blood Cells, White Blood Cells
|
Days 1, 3
|
Number of participants with abnormal changes of total IgE
Time Frame: Days 1, 3
|
Days 1, 3
|
|
Number of participants with abnormal neurological examinations
Time Frame: Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Days 1, 3, 7, 28+3 (for participants with 1 vaccination), Days 1,3,7,28+3,56±3 (for participants with vaccination and revaccination)
|
Collaborators and Investigators
Investigators
- Study Director: Ellina Ruzanova, PhD, St. Petersburg Research Institute of Vaccines and Sera
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLМ-ТЕ-05-2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaccine Reaction
-
PT Bio FarmaCenter for Child Health Universitas Gadjah Mada (CCH-PRO UGM; Cipto Mangunkusumo... and other collaboratorsRecruitingVaccine Adverse Reaction | Vaccine ReactionIndonesia
-
PharmaJet, Inc.National Cancer Institute (NCI); National Institutes of Health (NIH)Not yet recruiting
-
IRCCS San Camillo, Venezia, ItalyCompleted
-
Lahore General HospitalActive, not recruitingVaccine ReactionPakistan
-
China National Biotec Group Company LimitedPeking University; Hubei Provincial Center for Disease Control and Prevention; Shaanxi Provincial Center for Disease Control and Prevention and other collaboratorsCompletedTo Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPVVaccination | Reaction - VaccineChina
-
Sungkyunkwan UniversityGovernment-wide R&D Fund project for infectious disease researchUnknownPneumococcal Vaccine Adverse ReactionKorea, Republic of
-
Bandim Health ProjectResearch Center for Vitamins and VaccinesCompletedVaccine Adverse Reaction | Vaccine Reaction | Infant Mortality | Heterologous Immunity | Infant Morbidity | Trained ImmunityGuinea-Bissau
-
Persephone BiosciencesTerminatedVaccine Adverse Reaction | Vaccine Response ImpairedUnited States
-
physIQ, Inc.Recruiting
-
PT Bio FarmaHasan Sadikin General HospitalNot yet recruitingDiphtheria Vaccine Adverse Reaction | Tetanus Vaccine Adverse Reaction | Pertussis Vaccine Adverse Reaction | Haemophilus Influenzae Type B Vaccine Adverse Reaction | Hepatitis B Vaccine Adverse ReactionIndonesia
Clinical Trials on Influenza vaccine [inactivated]
-
Emory UniversityRecruitingFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin LymphomaUnited States
-
Hualan Biological Engineering, Inc.Completed
-
The University of Hong KongCenters for Disease Control and PreventionActive, not recruiting
-
St. Petersburg Research Institute of Vaccines and...CompletedInfluenza, Human | Vaccination; Infection | VaccinesRussian Federation
-
Richard Zimmerman MDCenters for Disease Control and PreventionCompletedImmune Response | Influenza, HumanUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsBelgium, Germany, Switzerland
-
SanofiCompletedInfluenza | Myxovirus InfectionUnited States
-
University of PennsylvaniaActive, not recruiting
-
Butantan InstituteFundação ButantanRecruiting
-
University of PittsburghSanofi Pasteur, a Sanofi CompanyCompleted